

# **Reportable Laboratory Findings**

Diseases Relating to Public Health - Form OL-15C

For information or to order forms call (860) 509-7994. (rev. 01/01/17)

## Connecticut Department of Public Health 410 Capitol Avenue, MS #11FDS P.O. Box 340308 Hartford, CT 06134-0308

Patient Last Name: First:	D.O.B Age:
	y: State/Zip Code:
Patient Telephone: Gender:	I Other specify: Hispanic/Latino: ☐ Yes ☐ No ☐ Unk.
Race:  White  Black/African Amer.  Asian  An	ner. Indian/Alaska Nat.    Nat. Hawaiian/Other Pacific Islander
☐ Other specify: ☐ Unknown Occupation: Name and address of workplace	If patient resides in a LTC facility please check: ☐ Yes
Attending Physician Last Name:	Ce:
	First:
	Telephone:
Person Reporting: Lab Telephone:	Specimen collection date:  Date laboratory finding reported to physician:
Submitting Laboratory: (name/address or label)	Date OL-15C completed:
, , , , , , , , , , , , , , , , , , ,	Hospital Chart No:Lab Specimen No:
	Source/Type specimen:
	Submitted to state lab: (see reverse) ☐ Yes ☐ No
☐ Anaplasma phagocytophilum by PCR only	☐ Mercury poisoning
□ Babesia □ IFA IgM (titer)IgG (titer)	□ Urine ≥ 35 μg/g creatinineμg/g □ Blood ≥ 15 μg/Lμg/L
☐ microti ☐ divergens ☐ duncani ☐ Unspeciated	d ☐ Mumps virus 12 (titer) ☐ PCR
☐ Bordetella pertussis (titer) ☐ Culture <sup>1</sup> ☐ Non-pertussis Bordetella <sup>1</sup> (specify)	☐ Mycobacterium leprae
☐ Culture · ☐ Non-pertussis Bordetella · (specify)	
□ Borrelia burgdorferi <sup>2</sup>	If positive ☐ Rare ☐ Few ☐ Numerous
☐ California group virus <sup>3</sup> spp	NAAT □ Positive □ Negative □ Indeterminate Culture □ Mycobacterium tuberculosis
☐ Carbapenem-resistant <i>Acinetobacter baumannii</i> <sup>1,4</sup> ☐ Carbapenem-resistant Enterobacteriaceae <sup>1,4</sup>	☐ Non-TB mycobacterium (specify <i>M</i> .)
Genus Spp	□ Neisseria gonorrhoeae (test type)
Genus Spp % COHb	□ Neisseria meningitidis, invasive 1,4 □ Culture □ Other
☐ Chikungunya virus ☐ Chlamydia trachomatis (test type)	☐ Neonatal bacterial sepsis <sup>13</sup> spp
☐ Clostridium difficile <sup>5</sup>	□ Plasmodium <sup>1,3</sup> spp
☐ Corynebacterium diphtheria <sup>1</sup>	□ Poliovirus □ Rabies virus
□ Dengue virus □ Eastern equine encephalitis virus	☐ Rickettsia rickettsii
☐ Ehrlichia chaffeensis by PCR only	□ Rotavirus
☐ Giardia spp	☐ Rubella virus <sup>12</sup> (titer) ☐ Rubeola virus (Measles) <sup>12</sup> (titer) ☐ PCR
☐ Group A Streptococcus, invasive <sup>1,4</sup> ☐ Culture ☐ Other ☐ Group B Streptococcus, invasive <sup>4</sup> ☐ Culture ☐ Other	☐ St. Louis encephalitis virus
☐ Haemophilus ducreyi	□ SARS-CoV ' □ IgM/IgG
☐ Haemophilus influenzae, invasive 1,4 ☐ Culture ☐ Other	☐ PCR (specimen) ☐ Other Done ☐ Staphylococcus aureus, invasive <sup>4</sup> ☐ Culture ☐ Other
☐ Hepatitis A virus (HAV) IgM anti-HAV <sup>6</sup> ALT AST ☐ Not I☐ Hepatitis B anti-HBs <sup>7</sup> ☐ Positive (titer) ☐ Nega	John C
☐ IgM anti-HBc ☐ HBsAg ☐ Positive ☐ Negative 7	☐ metnicillin-sensitive
☐ Hepatitis C virus (HCV) ☐ Rapid antibody ☐ RNA <sup>8</sup> ☐ Genotype <sup>8</sup>	☐ Staphylococcus aureus, vancomycin MIC ≥ 4 μg/mL <sup>1</sup>
☐ Herpes simplex virus (infants ≤ 60 days of age) (specify type)	MIC to vancomycinµg/mL — Staphylococcus epidermidis, vancomycin MIC ≥ 32 μg/mL <sup>1</sup>
☐ Culture ☐ PCR ☐ IFA ☐ Ag detection ☐ HIV Related Testing (report only to the State) 9	MIĆ to vancomycinµg/mL □ Streptococcus pneumoniae
☐ Detectable Screen (IA)	☐ Streptococcus pneumoniae ☐ Culture <sup>1,4</sup> ☐ Urine antigen ☐ Other <sup>4</sup>
Antibody Confirmation (WB/IFA/Type-diff) 1,9	□ Treponema pallidum
HIV 1 □ Positive □ Negative/Ind HIV 2 □ Positive □ Negative □ HIV NAAT (or qualitative RNA) □ Detectable □ Not Detectabl	erind Directivery Directive Directiv
☐ HIV Viral Load (all results) <sup>9</sup>	le □ VDRL (titer) □ TPPA □ Trichinella
☐ HIV genotype <sup>9</sup>	☐ Varicella-zoster virus, acute
☐ CD4 count: cells/uL;% <sup>9</sup> ☐ HPV (report only to the State) <sup>10</sup>	☐ Culture ☐ PCR ☐ DFA ☐ Other ☐ West Nile virus
Biopsy proven □ CIN2 □ CIN3 □ AIS	☐ Yellow fever virus
or their equivalent, (specify) ☐ Influenza virus ☐ Rapid antigen <sup>2</sup> ☐ RT-PCR ☐ Culture-confir	☐ Zika virus
☐ Unfluenza virus ☐ Rapid antigen 2 ☐ RT-PCR ☐ Culture-confir	med BIOTERRORISM possible disease indicators 19
Subtype:	☐ Burkholderia mallei <sup>1</sup> ☐ Burkholderia pseudomallei <sup>1</sup>
☐ Lead poisoning (blood lead ≥10 μg/dL <48 hrs; 0-9 μg/dL monthly) 11	☐ Clostridium botulinum ☐ Coxiella burnetii
☐ Finger stick lead levelµg/dL ☐ Venous lead levelµg/dL	<ul> <li>☐ Francisella tularensis</li> <li>☐ Staphylococcus aureus - enterotoxin B ☐ Variola virus <sup>1</sup></li> </ul>
☐ Legionella pneumophila	☐ Venezuelan equine encephalitis virus
☐ Culture ☐ DFA ☐ Ag positive ☐ Four-fold serologic change (titers)	☐ Viral agents of hemorrhagic fevers ☐ Yersinia pestis 1
SPECIFIC DISEASES RELATING TO FOODBORNE ILLNESS ACTIVE SURVEILLANCE NETWORK (FoodNet)	
☐ Campylobacter <sup>3</sup> spp	· · · · · ·
☐ Cryptosporidium spp	☐ Shiga toxin <sup>1</sup> ☐ Stx1 ☐ Stx2 ☐ Type Unknown
☐ Cyclospora spp	☐ Shigella 1,3 (serogroup/spp)
□ Escherichia coli O157 <sup>1</sup>	□ Vibrio <sup>1,3</sup> spp
☐ Listeria monocytogenes <sup>1</sup>	☐ Yersinia, not pestis <sup>3</sup> spp
Specify all methods yielding positive result:   Culture   PCR   EIA   Other:  Culture   PCR   EIA   Otheria   Otheri	
Patient status when specimen collected: ☐ Hospitalized ☐ Outpatient ☐ Unk. If outpatient, was patient later hospitalized? ☐ Yes ☐ No ☐ Unk.  If hospitalized, Hospital Name: Date Discharged:	
confirmation. For Salmonella, Shigella, and Vibrio tested by according to DPH	all C. difficile positive stool samples  10. If adequate tissue is available, send fixed tissue from the specimen used to diagnose CIN 2, 3 or
	iver function tests (ALT, AST) cervical AIS or their equivalent for HPV typing one week of patient's HAV IgM according to DPH instructions.
stool specimen. For Shiga toxin-related disease, send positive test, if available to stool specimen.	ailable. Check "Not Done" when
positive broth or stool in transport media. For positive HIV, appropriate. send ≥ 0.5mL residual serum. 7. Negative HBsAq;	the Local Health Director and the DPH; submit ALL lead results at least monthly to the DPH only.
2. Only laboratories with electronic file reporting are required only for children ≤	\$ 2 years old. 12. Report all IgM positive titers, but only IgG titers that
3. Specify species/serogroup/serotype. results only report	sults. Genotypes and Negative RNA are considered significant by the laboratory performing the test.
4. Sterile site: defined as sterile fluids (blood, CSF, 9. Report all HIV and	tibody, antigen, viral load, and results. HIV genotype (DNA an infant ≤ 72 hours of age.
internal body site (lymph node, brain, heart, liver, spleen, sequence) and all	I CD4 results are reportable by 14. Report by telephone to the DPH, weekdays 860-
kidney, pancreas, or ovary), or other normally sterile site electronic file. including muscle. For CRE and CRAB, also include urine or	509-7994; evenings, weekends, and holidays 860- 509-8000.
sputum, but not stool; and for CRAB also include wounds.	



This form must be completely filled out by the primary laboratory. Excerpts from the regulations of the State of Connecticut are given below.

# ANNUAL LIST (Section 19a-36-A2)

An annual list of the laboratory reportable significant findings will be prepared and mailed to directors of clinical laboratories licensed, registered, or approved by the Department of Public Health (DPH). Please refer to the current list when reporting findings since the list will be reviewed annually and revised when necessary.

# **RESPONSIBILITY FOR REPORTING** (Section 19a-36-A3)

The director of a laboratory that receives a primary specimen or sample which yields a reportable laboratory finding shall be responsible for reporting such findings within forty-eight (48) hours to the local director of health of the town in which the affected person normally resides, or, in the absence of such information, of the town from which the specimen originated, and to the DPH on forms provided by the DPH.

#### REPORTING (Section 19a-36-A4)

Each report should include:

- 1. Name, address and phone number of the person reporting and of the physician attending;
- 2. Name, address, date of birth, age, gender, race/ethnicity, and occupation of person affected;
- 3. Identity of the infectious agent or other reportable laboratory findings and date of collection;
- 4. Method of identification.

Reports must be mailed in envelopes marked "CONFIDENTIAL" within 48 hours of making the finding to the:

- 1. Local Director of Health of town in which the patient resides (Canary)
- 2. Connecticut Department of Public Health
  410 Capitol Avenue, MS#11FDS
  P.O. Box 340308
  Hartford, CT 06134-0308

or submitted in a manner specified by the DPH.

# **CONFIRMATION** (Section 19a-36-A3(b)(1))

When a laboratory identifies or presumptively identifies a significant isolate or other finding that requires confirmation by the laboratory as required in the annual list, the director must submit the isolate or specimen from which the finding was made to the Department's laboratory division.

# HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA) GUIDELINES

Pursuant to Connecticut General Statutes § 19a-2a and § 19a-215 and to the Regulations of Connecticut State Agencies §s 19a-36-A3 and §s 19a-36-A4 as cited above, the requested information is required to be provided to the Department of Public Health.

Please note that CGS § 52-146o(b)(1) authorizes the release of these records to the Department without the patient's consent. Additionally, the federal Privacy Regulations of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) also authorize you, as a provider, to release this information without an authorization, consent, release, opportunity to object by the patient, as information (i) required by law to be disclosed [HIPAA Privacy regulation 45 CFR § 164.512(a)] and (ii) as part of the Department's public health activities [HIPAA Privacy regulation, 45 CFR § 164.512(b)(1)(i)]. The requested information is what is minimally necessary to achieve the purpose of the disclosure, and you may rely upon this representation in releasing the requested information, pursuant to 45 CFR § 164.514(d)(3)(iii)(A) of the HIPAA Privacy regulations.